





an Open Access Journal by MDPI

Molecular Insights into Osteosarcoma

Guest Editors:

Dr. Fan Shen

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2B7, Canada

Prof. Dr. Consolato M. Sergi

1. Division of Anatomic
Pathology, Children's Hospital of
Eastern Ontario, University of
Ottawa, Ottawa, ON, Canada
2. Department of Laboratory
Medicine and Pathology,
University of Alberta, Edmonton,
AB. Canada

Deadline for manuscript submissions:

30 September 2024

Message from the Guest Editors

Dear Colleagues,

The quote "Cellular pathology is not an end if one cannot see any alteration in the cell. Chemistry brings the clarification of living processes nearer than does anatomy. Each anatomical change must have been preceded by a chemical one." as stated by Rudolf Virchow (Coper, H., Herken, H., 1963. Dtsch. Med. Wochenschr. 88, 2025–2036). Osteosarcoma is a comparatively painstaking topic for many paediatricians, paediatric surgeons, and paediatric pathologists, because despite progress in numerous paediatric malignancies, the outcomes of the affected individuals are still quite poor.

We would be very grateful to gather basic science articles and clinical reports for this Special Issue, which concentrates on the molecular insights of osteosarcoma. As Virchow stated, a chemical change is the basis of what the pathologists sees under the microscope and the physician can assess clinically. We hope to receive several contributions that may attract the attention of funders and charities in promoting more research in the relatively poorly explored field of pre-cancerous bone histology.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us